Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Somatogen (SMTG) -- Ignore unavailable to you. Want to Upgrade?

To: jackie who wrote (342)	12/15/1997 4:30:00 PM
From: biowa	Respond to of 442

Jack, >>Anyone want to talk about prions?<< Have to admit I don't know the answer to that one, except to say that I assume Biopure's product is sourced here in the U.S. where BSE has not been detected. In addition, its my understanding that blood has a fairly low rate of transmission of BSE. I also suspect that the processing of the product might remove or inactivate any prions that were present. I suspect the same issue could be raised with transfusion transmission of CJD from human donors, as well as with the Baxter and NFLD human-based products. If this is an issue, which the FDA should have raised before allowing Baxter to initiate its PIII trial, then SMTG is in an obvious winning position. Dr. Barai, Thank you for your kind invitation. I would certainly enjoy joining the discussions on this thread. Right now I'm waiting for a copy of the Cowen report on the blood substitutes meeting in Cambridge last month. After I get a chance to read it, perhaps there will be something of note we can discuss. Regards, biowa